May 20, 2024 – Page 6 – Goldea Capital

Gray Announces Private Offering of Senior Secured Notes

Written by Customer Service on May 20, 2024. Posted in Public Companies.

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) announced today that it intends to offer up to $1 billion aggregate principal amount of senior secured first lien notes due 2029, subject to market conditions. The offering will be exempt from the registration requirements of the Securities Act of 1933 (the “Securities Act”). In connection with the offering of notes, Gray expects to (i) incur up to $750 million of a new tranche F term loan with a maturity date in 2029, (ii) increase the aggregate commitments under its existing $625 million revolving credit facility by $55 million, resulting in aggregate commitments under the revolving credit facility of $680 million and (iii) terminate commitments under a $72.5 million tranche of the revolving credit facility maturing in 2026...

ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING

Written by Customer Service on May 20, 2024. Posted in Public Companies.

AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: e16318. Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in patients with pancreatic adenocarcinoma harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen. Abstract: e14564. The prognostic impact of transforming growth factor beta 2 (TGFB2) mRNA levels, in conjunction with interferon-gamma receptor activation of interferon regulatory factor 5 (IRF5) and expression of CD276/B7-H3 in low-grade gliomas. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was...

Bridger Aerospace Responds to Concerns Over Politically Motivated Attacks on its Business

Written by Customer Service on May 20, 2024. Posted in Public Companies.

BELGRADE, Mont., May 20, 2024 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today responded to questions from various constituencies as a result of recent politically-motivated attacks on its business in certain media outlets. In recent weeks, candidates for political office and their allied political organizations have written disparaging articles and launched partisan attacks against the Company. They have assembled a mosaic of publicly available information, out of context corporate statements and negative legal risk factors and disclaimers to weave together an unflattering narrative in media reports regarding the financial health of Bridger. These statements highlight Bridger’s 2023...

NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

Written by Customer Service on May 20, 2024. Posted in Public Companies.

SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company advances SNK01 into Phase 2 in moderate Alzheimer’s disease; first patient enrolled in Phase 2 expected in Q2 2024. SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that its Safety Review Committee has cleared the Company’s cryopreserved autologous, expanded and enhanced SNK01 to progress into Phase 2 clinical development. NKGen’s initial “proof of concept” Phase 1 study was an open...

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Written by Customer Service on May 20, 2024. Posted in Public Companies.

BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to...

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Written by Customer Service on May 20, 2024. Posted in Public Companies.

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company’s mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer prevention BERKELEY, Calif. and MAINZ, Germany, May 20, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, unveiled key findings from its groundbreaking eAArly DETECT study during a poster presentation at the renowned Digestive Disease Week (DDW) 2024 in Washington D.C. The...

Nexxen Reports Results for the First Quarter Ended March 31, 2024

Written by Customer Service on May 20, 2024. Posted in Earnings Releases And Operating Results.

Generated record Q1 programmatic revenue, 34% year-over-year Adjusted EBITDA growth, and $37.7 million net cash from operating activities Reaffirming full year 2024 Contribution ex-TAC and Adjusted EBITDA guidance Completed $20 million Ordinary share repurchase program and launched additional $50 million program Strengthened balance sheet through repayment of outstanding $100 million long-term debt NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) — Nexxen International Ltd. (AIM/NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, unified advertising technology platform with deep expertise in video and Connected TV (“CTV”), announced today its financial results for the first quarter ended March 31, 2024. Financial Summary Contribution ex-TAC: Generated Contribution ex-TAC of $69.7 million in Q1 2024, reflecting a 4% organic increase...

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

Written by Customer Service on May 20, 2024. Posted in Public Companies.

Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptoms Planned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCR CDC estimates CFS affects 3.3 million Americans WASHINGTON, May 20, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it will fund Babesia spp testing in chronic fatigue patient samples in a study to be conducted by North Carolina State College...

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Written by Customer Service on May 20, 2024. Posted in Public Companies.

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions. All of the shares of common stock in the offering are to be sold by Foghorn. Foghorn anticipates the total...

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

Written by Customer Service on May 20, 2024. Posted in Public Companies.

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada. “I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay. “OCU400 modifier gene therapy represents a breakthrough approach for the potential treatment of broader retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA)...

Day: May 20, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice